U
AGIO icon

UBS’s Agios Pharmaceuticals AGIO Stock Holding History

UBS’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$12K Buy
200
+100
+100% +$4.31K ﹤0.01% 8610
2014
Q2 		$5K Buy
+100
New +$4.08K ﹤0.01% 9474

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's AGIO Position: Q3 2014 in Review

UBS increased its Agios Pharmaceuticals (AGIO) stake by 1,255% in Q3 2014, buying an estimated $1.03M and bringing the position to 25,875 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #3128.

UBS first reported a position in AGIO in Q3 2013 and has held it in 5 quarters since. 120 funds tracked by Wall St. Rank hold AGIO as of Q3 2014.

  • UBS held 25,875 shares of Agios Pharmaceuticals worth $1.59M as of Q3 2014.
  • UBS bought 23,966 Agios Pharmaceuticals shares in Q3 2014, an estimated $1.03M.
  • Agios Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3128 holding.
  • UBS first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 5 quarters since.
  • 120 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.